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Abstract
Background and aims: Treatment of inflammatory bowel diseases (IBD) is only aimed to block or
inhibit the pathogenetic steps of the inflammatory cascade. Side effects of systemic therapies,
poor targeting of orally administered topical drug and low adherence to prescription represent
frequent therapeutic challenges. Recent observations suggest that nanotechnology could
provide amazing advantage in this field since particles having dimension in the nanometer
scale (nanoparticles) can modify pharmacokinetic step of biologic and conventional therapeutic
agents with a better delivery of drugs within the intestinal inflammatory cells. The aim of this
review was to provide the clinician with an insight into the potential role of nanotechnology in
the treatment of IBD.
Methods: A systematic search (PubMed) for experimental studies on the treatment of intestinal
inflammation using nanotechnology for the delivery of drugs.
Results and conclusions: The size of the pharmaceutical formulation is inversely related to
specificity for inflammation. Nanoparticles can penetrate epithelial and inflammatory cells
resulting in much higher, effective and long-acting concentrations than can be obtained using
conventional delivery systems. From a practical point of view, this should lead to improvements
in both efficacy and adherence to treatment, providing patients with the prospect of stable andowel diseases; 5-ASA, 5-aminosalicylic acid, mesalazine; UC, ulcerative colitis; CD, Crohn's disease;
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904 A. Viscido et al.prolonged remissions with reduced drug loadings. Reduced systemic side effects could also be
expected.
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A definitive cure for inflammatory bowel diseases (IBD) is still
lacking and patients continue to be treated with agents aimed
at blocking or inhibiting the immune-inflammatory cascade at
various levels. In active ulcerative colitis (UC), mesalazine
(5-aminosalicylic acid: 5-ASA) is effective in mild to moderate
diseases, while steroids, cyclosporine and biologics becoming
necessary in severe presentations.1 For active Crohn's disease
(CD), for which cyclosporine is ineffective and 5-ASA has a
limited role, it is still debated whether biologics should be
used as first line treatment or only for patients who prove
refractory to steroids.2 With regard to the maintenance of
remission, biologic drugs, immunosuppressants and 5-ASA can
each in their own way prove effective.1,2 Biologics have been
studied in recent years and some concern exists about the real
burden of long-term adverse effects including opportunistic
infections and malignancies.3 Moreover, it is not clear when
they can be stopped or which is the best exit strategy.4
Immunosuppressants are effective and strongly indicated for
steroid-dependent patients, but doubt remains regarding
their safety for applications longer than 5 years.1,2 5-ASA, on
the other hand, has been in use frommore than 70 years, with
proven efficacy and only modest long-term side effects, with
limitations however, regarding its topic action and complex
therapeutic protocol.5–10 In fact, in UC and in prevention of
recurrence in CD, the major problem is to maintain an
adequate concentration of the drug in the inflamed mucosa
in order to obtain a reduction of recurrences and reduce the
need of steroids and hospitalization.11–15 These results,
sometimes may require multiple daily administrations of
large numbers of pills — together with enemas, suppositoriesor foam, a practice that has the effect of reducing a full
adherence to treatment in about half of patients with a
fivefold increased risk of recurrence.16,17 Thus, the ideal drug
to treat IBD should focus specifically on inflamed tissues with
the fewest systemic involvement, simplifying therapeutic
protocols and assuring maximum adherence to treatment. To
date, only the recent formulation MMX 1200 mg, aside the
possibility of a once-a-day administration, allows a reduction
in the number of pills and a wider colonic targeting.18,19
In the last years, new technologies provided opportunities
for advances in this field. In particular, nano- and
micro-particles have turned out to be promising tools for the
targeted delivery of drugs to specific anatomical sites.20–22
Nanomedicine, which refers to the application of nanotech-
nology to medicine, is an emerging area, which focuses in
imaging, early diagnosis, pathological tissue analysis and
especially in drug delivery. In particular, it can allow not
only the development of new therapeutic agents, but also the
improvement in efficacy of existing drugs.23–28
The aim of this paper is twofold: to provide an overview of
the literature aimed to synthesize the main physico-chemical
characteristics of nano- andmicro-particles and to explore the
potential role of nanotechnology in the treatment of intestinal
inflammation.2. Methods
A literature search was conducted using PubMed with the
search terms “inflammatory bowel diseases”, “intestinal
inflammation”, “nanotechnology”, “nanoparticles”, “micro-
particles”, “drug targeting”, and “therapy”. All the
905Nanotechnology in IBDexperimental studies on the treatment of intestinal inflam-
mation using nanoparticles and microparticles for the
delivery of drugs were included. Further relevant articles
were identified from the reference lists.
2.1. Nanotechnology
Nanotechnology entails the synthesis and manipulation of
particles having dimensions in the nanometer range.29 One
nanometer (nm) is one billionth, or 10−9, of a meter. To get
an idea of the scale, the diameter of a DNA double-helix is
about 2 nm, the smallest atom, hydrogen, has a diameter of
approximately 0.25 nm and the distance between two
bonded atoms of carbon in a molecule is about 0.1 nm. On
the other hand, the smallest bacteria, those of the genus
Mycoplasma, are about 200 nm (Fig. 1). Particles in
nanometric size range are termed nanoparticles (NPs). The
size greatly depends on the process used for their synthesis.
They can be obtained by bottom-up assembly of atoms
through chemical process or, on the contrary, from
top-down fragmentation of bulk material. The former
method allows the synthesis of smaller particles.29 NP
properties are governed by three main features: size,
composition, and geometry (Table 1).23,26,29
2.1.1. Size
The scale range for NPs has been assumed by convention to
be 1 to 100 nm.29 The lower limit is set by the size of atoms
since nanotechnology must build its particles from atoms
and molecules. The upper limit is somewhat arbitrary but
relates to the size that permits the desired implementation
that is not feasible at larger scales, such as penetration of
cells.23,26 The upper cut-off size for medical implementation
can be therefore considered 1000 nm (1 micrometer — μm),
as this size permits penetration of non-phagocytic eukary-
otic cells,30 even if, phagocytic cells such as dendritic cells+
2 nm: diamete
200 nm: Mycop
0.25 nm: hydro
8000 nm: red b
Figure 1 Illustration representing the sizeand macrophages can eat by phagocytosis larger particles up
to 4 μm in size.31 Particles greater than 1000 nm are called
micro-particles. NPs have unique physicochemical proper-
ties which are distinct from those of the same material with
larger macroscopic or microscopic sizes. The most intriguing
property is their ability to escape the forces of the Newton's
laws of motion, being governed by the laws of quantum
mechanics.29 When observing their behavior suspended in a
solution, movements of NPs are very dynamic, and they
move rapidly and are randomly driven by Brownian motion.32
Of particular significance in medical applications is their
very high surface-to-mass ratio — a property that increases
progressively with decreasing in size. This large functional
surface is able to bind, absorb and carry many compounds
such as probes, proteins and drugs, thus making NPs
particularly attractive for medical delivery purposes.23,26,29
Nano-size is the cardinal property for interaction with
biological systems since it determines the ability to
penetrate cell membranes, thus facilitating the passage
across biological barriers, interaction with immune system,
uptake, absorption, distribution and metabolism.23,33 For
instance, size of orally assumed NPs could somehow
determine its fate addressing the kind of cell to interact
(i.e. epithelial or phagocytic cell), or the depth level in the
intestinal mucosa.30,31,33,34
2.1.2. Composition
Composition of NPs may be of biologic or chemical origin.
Biologic materials include phospholipids, lipids, lactic acid,
dextran, chitosan, and albumin. Chemical materials include
polymers, carbon, silica, and metals. Polymers, in turns,
may have different chemical compositions. Chemistry is of
crucial importance in safety issues as some nanosized
constituents can result toxic.23 The surface chemical
composition determines the first interaction of NPs with
tissues and cells, the surface charge being one of the majorr of a DNA double-helix
lasma (the smallest bacteria)
gen atom (the smallest atom)
lood cell
of different structures in the nm range.
Table 1 Nanoparticle properties for medical implementation.
Feature Actions (performance)
Size – b1000 nm
– High surface-to-mass ratio
– Penetration of cells
– Passage across biological barriers
– Reaching deep strata of intestinal mucosa
– Binding drugs
Composition – Biologic
– Chemical
– First interaction with biological barriers
– Surface charge and hydrophilicity
– Porosity (controlled release of drugs)
– Functionalization of surface
– Toxicity
Geometry – Spherical
– Tubular
– Disk- or road-shaped
– Extent of contact surface
– Adhesion to biological barriers
– Toxicity
906 A. Viscido et al.aspects together with their hydrophobicity/hydrophilicity
characteristics.35 The charge has many properties such as
that of stabilizing the dispersion of particles in solution,
preventing their aggregation and give stability to the NP
suspension.26 For medical purpose, the surface charge can
be used to increase the proximity of NPs to the epithelium,
increase its absorption and determine different interactions
with the intestinal epithelium. For example, positively
charged NPs have a strong affinity for healthy epithelium,
whereas negatively charged particles preferentially adhere
to inflamed mucosa.36,37 Hydrophilicity, in turn, may
contribute to tissue absorption enhancing penetration of
the intestinal mucus layer.26 Another important aspect of
NPs is porosity that is a measure of void spaces in a material.
Porous materials possess vast amounts of nanopores that
allow the inclusion and retention of drugs, modulating their
release in order to obtain controlled and sustained drug
delivery systems.38 Further surface properties may be
imparted to NPs by coating them with various substances.
Polyethylene glycol (PEG), for example, enables the NPs to
avoid immune recognition following intravenous administra-
tion or resist enzyme degradation following oral administra-
tion.39,40 Moreover, coating with polymers or antibodies,
that bind specifically to a particular cell, can help to better
achieve targeted drug delivery.412.1.3. Geometry
The penetrating capability of a NP across a biologic surface
depends also on the contact area and the curvature of the
particle at the contact point. Thus, the geometrical shape
represents an important characteristic for NP performance.
The disk-shaped or road-shaped NPs have the largest
adhesion probability mainly due to the larger surface area
available for contact and multivalent interactions,42 giving
rise to a larger drug flux per unit volume.43 However,
nowadays, experimental studies have mostly been conduct-
ed with spherical (liposomes, emulsions, capsules, spheres)
or tubular (nanotubes) NPs, due in part to fabrication
technology limitations in controlling their shape. The
energy-minimizing principles involved in the bottom-up
production techniques for stable structures determine the
spherical shape, because spheres have the least surface per
unit volume and, thus, minimize the interfacial energies.
The advancement of techniques involved in nanofabricationhas enabled the development and production of various
non-spherical NPs. A note of warning has to be made as it has
been supposed that nanocrystalline particles by themselves
may have a biologic effect on cells. For example, while the
α-quartz form of silica results pro-inflammatory due to
lysosomal rupture following cellular uptake, amorphous
silica particles do not induce any lysosomal response.44
To synthesize, size, surface chemistry and shape confer
to NPs an ability to enter cells, to carry compounds and
influence cellular functions much greater than correspond-
ing conventional agents. These properties entailed the
development of nanopharmacology, a new field of research
meant to better driving drugs to specific targets.
2.2. Nanopharmacology
Nanopharmacology has been defined as the application of
nanotechnologies to drug design and drug delivery.45 Drug
delivery itself dominates the whole nanomedicine sector,
accounting for 76% of publications, 59% of patents, and a
steady growth up of investments.46 The main purpose of
nanopharmacology, currently, is to study new formulations
of drugs that are able to improve their pharmacokinetic and
dynamic profiles.45 The great potential for such strategies is
testified by the growing number of FDA-approved NP-carried
drugs.46
The usual course of a drug after administration follows
the kinetic processes of absorption, distribution, metabolism
and elimination. The rates of these processes determine the
concentration and the retention of the compound at site of
action, and therefore the extent of the consequent dynamic
response. Therapeutic response occurs when drug concen-
tration at the site of action is sufficient to promote a
favorable effect, without toxicity. Therapeutic index de-
fines the margin between the effective and toxic doses. It
results optimized when the formulation allows easily
overtaking the biological barriers that separate the site of
administration from the site of action, and when the drug is
released into the target cell with the least possible systemic
concentration.26 This condition can easily be achieved
taking advantage of the numerous physico-chemical charac-
teristics of NPs that allow overcoming biologic barriers,
entering inside cells and release the drug in a controlled and
sustained manner. In fact, the small size can increase
907Nanotechnology in IBDluminal residence times as NPs are relatively uninfluenced
by luminal streaming, thereby enhancing the probability of
adhesion and penetration to the mucosa.47–49 Secondly, the
Brownian motions of the NPs suspended in the luminal
content increase the probability of adhesion to mucosa.32,50
Moreover, as observed in in vitro models, small size could
facilitate endocytosis and transcytosis, responsible for
uptake of particles of less than 100 nm and 500 nm in
diameter respectively.33,41 Taken together, these charac-
teristics allow NP absorption rate up to 15–250 fold higher
compared to larger size particles.20
In inflammatory conditions (Fig. 2), the intestinal
epithelial line loses its function of barrier due to disruption
of the anatomic integrity. Persorption, the passage through
“gaps” or “holes” at the epithelial line following loss of
cells, greatly enhances the entry of NPs into mucosa.47,51
Once into tissue, the small size enhances the retention time
at the target site via bioadhesion, although the exact
mechanism of accumulation is not fully understood. More-
over, NPs can directly enter into phagocytic cells that
populate the inflamed tissue, thus providing a wider
distribution and an additional mechanism for NP reten-
tion.31,33,47,52 The transport of small particles in the
inflamed intestinal mucosa has been recently studied in
patients with active IBD, a unique scenario in the field of
drug targeting since the site of action matches with that of
absorption and consequently drugs do not need access to the
systemic circulation to act. NPs (250 nm) and microparticles
(3.0 μm) were placed in the intestinal lumen of IBD patients
and in that of healthy controls. In the presence ofMicro-particle
Nanoparticles 
Brownian motions
PERSORPTION OF NANO
Macrophage
Figure 2 Schematic representation of the mechanisms that favor
influenced by intestinal luminal streaming resulting in increased lu
driven by the Brownian motions that increase the probability of ad
favored by the presence of the thicker mucus layer surrounding the
enter into tissue due to mechanism of “persorption”. (D): Once that
is an additional mechanism favoring NP retention. (E): Transport acro
particles; NPs reach the deeper layers of the mucosa while micropamild-to-moderate inflammation, both NPs and microparti-
cles are increased in the areas of epithelial lesions,
suggesting persorption of particles through cellular voids.
Transport across inflamed colonic mucosa, however, turned
out to be dependant on particle size: the larger micropar-
ticles being retained in the more superficial layers of the
mucosa and the smaller NPs penetrating to greater depths.
This data could reflect a size-dependent limitation of the
persorptive capacity of particles, with NPs being able to
more rapid transit from the surface to deeper layer of the
intestinal wall.34
All the above-mentioned mechanisms and characteristics
could indicate that, using oral NPs as a drug-carrier, it is
possible to take drugs more easily inside target tissues
improving the efficiency of each kinetic step and possibly
the efficacy of therapeutic action.
Five kinds of nanosized carrier systems can be consid-
ered: water soluble polymer, emulsion, nanosphere, lipo-
some, polymeric micelle. The water-soluble polymeric
carriers include both naturally occurring and synthetic
polymers (including antibodies). Emulsions comprise small
oil droplets stabilized with an outer amphiphilic layer.
Nanospheres are solid small particles made from natural or
synthetic polymers. The difference between emulsions and
nanospheres is the status of the interior, liquid for emulsions
and solid for nanospheres. Liposome is a vesicle consisting of
a lipid bi-layer that mimics cellular membranes. Polymeric
micelles are the newest type of drug carrier systems. They
are macromolecular assemblies of polymers with a spherical
inner core and an outer shell.22 In general a carrier must beA
B
C
D
E
/MICRO PARTICLES
the absorption of particles in the nm scale: (A) NPs are scarcely
minal residence; (B) NPs suspended in the luminal content are
hesion to mucosa. Furthermore, adhesion to mucosa is greatly
lesions; (C) in the presence of mucosal inflammation NPs easily
NPs have gained access to mucosa, phagocytosis by macrophages
ss inflamed intestinal mucosa is different for the different sized
rticles are retained in the more superficial layers.
908 A. Viscido et al.produced from materials that are biodegradable or, if not,
residual material after drug delivery should be non-toxic.23
Two main strategies are used to load the drug to NP
carriers: (1) covalent linkage to a polymer matrix and (2)
encapsulation in a hollow coat.22 Presently, both strategiesTable 2 Biologic therapy: block of inflammatory mediators.
Biologic agent Vector Size (z) Experimental
model
Nanobodies
against TNFα
Lactococcus
lactis
– DSS colitis,
IL10−/− mice
siRNA-TNFα Thioketal 600 nm DSS colitis
PLA (matrix)
PVA (shell)
380 nm
(z: −8 mV)
LPS colitis
NiMOS
PCL
2–4 μm DSS colitis
Mannose 240 nm DSS colitis
siRNA-cyclin Antibodies
toward
β7 integrin
(on surface)
100–160 nm
(z: −20 mV)
DSS colitis
siRNA-TNFα +
siRNA-cyclin
NiMOS
PCL
2–4 μm DSS colitis
siRNA-Map4k4 Glucan 2–4 μm LPS colitis
Antisense-DNA
nucleotide
toward NF-kB
Chitosan-PLGA 370 nm
(z: +13 mV)
DSS colitis
TNFα: tumor necrosis factor α; siRNA: short interfering RNA; Map4k4: mit
factor-κB; PLA: poly-lactic acid; PVA: poly-vinyl alcohol; NiMOS: N
poly(lactic-co-glycolic acid); z: surface charge; DSS: dextran sodium sulf
oxygen species; IL: interleukin; IFN: interferon; Cy: cyclin; GALT: gutare realized using water soluble polymeric carriers, the
same used in the pioneer study aimed to evaluate the
targeting of intestinal inflammation by NPs. This study was
conducted using poly(lactic-coglycolic acid) (PLGA), to
encapsulate rolipram, a drug with anti-tumor necrosis factorResults Ref.
– Neutralization of both soluble
and membrane-bound TNFα;
– Amelioration of inflammation
(histological score; MPO-activity);
– Action restricted to intestine without
systemic effects.
60
– Release of the encapsulated agent in response
to ROS;
– Inhibition of TNFα gene expression
only in inflamed intestinal tissue;
– Amelioration of inflammation
(histological and clinical scores; MPO-activity).
62
– Efficiently taken up by macrophages;
– Inhibition of TNFα secretion from macrophages;
– Amelioration of inflammation (TNFα levels);
– Inhibition of inflammation restricted to colon.
63
– Amelioration of inflammation
(histological and clinical scores;
MPO-activity; TNF-α, IL-1β, IFN-γ, chemokine
levels).
64
– Specific uptake by macrophages
due to mannose receptors;
– Amelioration of inflammation (histological
and clinical scores; TNFα levels).
65
– Specific uptake by leukocytes;
– Reversal of inflammation (histological
and clinical scores; TNFα, IL-12
levels — not IL-10; leukocyte proliferation).
66
– Amelioration of inflammation (histological
and clinical scores; MPO-activity; CyD1,
TNF-α, IL-1α and β, IFN-γ, chemokine levels);
– Silencing of CyD1 or dual silencing
(CyD1 + TNFα) were more potent than TNFα
silencing alone.
67
– Specific uptake by GALT macrophages
due to glucan receptors;
– Prevention of inflammation
(TNFα and IL-1β production);
– The in vivo potency of oral delivery in
gene silencing is 5 to 250 times
greater than systemic delivery
(reported in previous studies).
68
– Specific uptake by inflamed mucosa;
– Amelioration of inflammation
(histological and clinical scores, MPO-activity);
– Inhibition of gene expression restricted
in inflamed mucosa.
69
ogen-activated protein kinase kinase kinase kinase 4; NF-κB: nuclear
Ps in microsphere oral system; PCL: poly-caprolactone; PLGA:
ate; LPS: lipopolysaccharide; MPO: myeloperoxidase; ROS: reactive
associated lymphoid tissue.
909Nanotechnology in IBD(TNF)-α effects. Either the rolipram solution or the rolipram
carrying NPs were able to decrease inflammation in a
trinitrobenzene sulfonic acid (TNBS) colitis. However, while
the effect of free solution vanished after few days, the
effect of rolipram NPs was significantly prolonged as drug
release in the NP system was found to be sustained over
1 week. This was the first observation that this nanosized
polymer allows a sustained drug release due to the retention
of the carrier system in the targeted inflamed area.53
Most of the subsequent studies on experimental models of
intestinal inflammation were performed using 3 kinds of
polymers: chitosan, PLGA and Eudragit.54 Chitosan is a naturally
occurring polysaccharide with excellent mucoadhesive proper-
ties. PLGA, a biodegradable polymer able to act as sustained
drug delivery system, is degraded in the body through hydrolysis
to lactic and glycolic acids, that are further metabolized in the
citric acid cycle. Eudragit, a pH sensitive material, is the same
polymer adopted for conventional bulk preparations. In an
experimental model, chitosan, PLGA-based and Eudragit NPs
showed no difference in the ability to target the site of
intestinal inflammation when compared each other. PLGA
delivered its content in intracellular compartment, chitosanTable 3 Biologic therapy: administration of anti-inflammatory m
Biologic agent Vector Size
(z)
Model
m IL-10 Lactococcus
lactis
– DSS colitis
IL-10−/− mic
rm IL-10 Gelatin
microspheres
b12 μm IL-10−/− mic
Rhu IL-10
(plasmid DNA
encoding
IL-10)
NiMOS
PCL
2–5 μm TNBS colitis
IL-10 Eudragit b4 μm Not used in a
Rhu prohibitin PLA 440 nm
(z: −5 mV)
DSS colitis
Trefoil Lactococcus
lactis
– DSS colitis
IL-10−/− mic
Lys-Pro-Val (KPV) PLA (core)
Alginate-chitosan
(capsule)
400 nm LPS colitis
m: murine; IL: interleukin; rm: recombinant mouse; rhu: recombinant
PCL: poly-caprolactone; PLA: poly-lactic acid; z: surface charge; DSS:
lipopolysaccharide; MPO: myeloperoxidase; IFN: interferon; TNFα: tumainly at cell membrane, while Eudragit in the medium.
Chitosan NPs had the highest apparent permeability in the
normal mucosa. An improvement in carrier strategy was
obtained when mannose was grafted on the PLGA based NPs.
The introduction of mannose to the surface of NPs provided
selectivity for macrophage targeting as the mannose receptors
are transmembrane proteins exclusively expressed on the
surface of macrophages. The result of this strategy, also called
active targeting, was that mannose-grafted PLGA NPs showed
the highest accumulation in inflamed colon, making it the most
promising approach for targeting inflammation.54 Active
targeting may also be obtained recovering NP surface with a
peptide or an antibody, to accumulate on a specific area before
releasing the active agent.26
In later studies polymers were used also in combination to
realize the “polymeric micelle” system of carrier. In this
system drug is firstly incorporated into a matrix by both
chemical conjugation and physical entrapment to realize the
inner core. Secondly the core is entrapped in an outer shell
composed by another polymer with other characteristics.22
For example, in order to minimize early drug release in the
proximal intestine, an inner core composed by a polymericediators.
Results Ref.
e
– Amelioration of inflammation in
DSS colitis;
– Prevention of the onset of colitis
in IL-10−/− mice.
71
e – Amelioration of inflammation
(macroscopic and histologic
scores; IL-12).
72
– Amelioration of inflammation
(macroscopic, histological and clinical
scores, MPO activity);
– Suppression of the expression of
inflammatory cytokines (IFN-γ, TNF-α,
IL-1α, IL-1β, IL-12) and chemokines.
73
nimals – Inexpensive. 74
– Amelioration of inflammation
(histological and clinical scores,
macroscopic findings by mouse
colonoscope, MPO activity);
– Reduction of the expression of
inflammatory cytokines (TNFα, IL-1β, IFNγ).
75
e.
– Amelioration of inflammation (macroscopic
and microscopic inflammation, MPO activity);
– prevention and healing of DSS colitis;
– Improvement of established chronic
colitis in IL-10−/− mice.
76
– Amelioration of inflammation
(histological score, MPO activity,
reduction of TNF α, IL1β).
– Effective dose 12000 times lower
respect to free KPV solution.
77
human; KPV: Lys-Pro-Val; NiMOS: NPs in microsphere oral system;
dextran sodium sulfate; TNBS: trinitrobenzene sulfonic acid; LPS:
mor necrosis factor α.
910 A. Viscido et al.matrix entrapping budesonide, was encapsulated within an
enteric pH-sensitive polymer (Eudragit) conferring to the
drug a significant enhancement of anti-inflammatory
activity.55
2.3. Nanoparticles Based Therapies in IBD
IBD represent a paradigm in the field of drug targeting since
they are characterized by segmental inflammation of the
bowel, directly exposed to an orally administered drug. In
UC mucosal lesions involve invariably the rectum and, to
various extents, the colon, but not the proximal bowel,
while in CD even if inflammation could involve the entire
bowel, it is usually present only in short segments and
sometimes in multiple sites. Thus, in IBD, the greatest part
of the bowel is normal and should not be exposed to any drug
to reduce or avoid systemic side effects. On this regard,
5-ASA is the most studied drug since it acts only topically and
cannot be given systematically.10 Similarly, budesonide and
beclometasone-dipropionate were also pharmaceutically
prepared to be delivered on target tissues.1,2 Action of
bacteria, luminal pH, and sustained release are, till now, the
methods used as delivery system.10 Such approximate
techniques cannot however prevent the release of a certain
amount of the drug on to normal mucosa, nor assure its
distribution over the whole area of inflamed tissues. NPs, in
view of their physico-chemical characteristics, their kinetic
after oral assumption, and their ability to discriminate
between diseased and non-diseased sites, would appear the
ideal delivery system in IBD, able to select specific target
sites such as mucosal inflammatory cells infiltrate, disrup-
tion of mucosal barrier, increased permeability, and in-
creased production of mucus. All these inflammatory
features represent target that could be selectively reached
by nanosized carriers, as the smaller is the particles, the
more selective is the focus on inflamed tissues.26,47 For
10 μm particles, only fair deposition is observed in inflamed
tissue; 1-μm particles showed a nearly 5-fold higher
percentage of particle binding in colitis compared to
controls, whereas the highest deposition in inflamed tissue
was found for 0.1 μm particles.21 This phenomenon can be
explained by a series of observations. Macrophages and
dendritic cells are able to uptake NPs and
microparticles.31–33 Cells other than phagocytes could
further uptake NPs as it has been observed that NPs can
activate autophagy.52 The enhanced permeability further
allows the accumulation of the carrier system at the
inflamed site, also because particles with a size smaller
than 200 μm are not subjected to diarrhea luminal stream-
ing resulting in increased residence time respect to larger
particles.56,57 Finally, an increased adherence of particles to
the inflamed tissue is observed at the thicker mucus layer
and in ulcerated regions, influencing in turn NP retention at
the mucosal surface.58
Below, the first experiences on both biologics and
conventional drugs are summarized.
2.3.1. Biologics
Tables 2 and 3 summarize studies on biologics. Neutraliza-
tion of TNFα was the first biologic strategy used in clinical
practice.59 However, anti-TNFα agents did not spread asexpected, in fear of possible side effects, mainly due to
their systemic implications.3 This limit could be overcome
by using NP delivery systems, since they could address the
drug almost exclusively to their specific site of action,
without systemic distribution and what is more, they can
be orally administrated. NPs being able to inhibit
TNFα have been realized through both nano-antibodies
(nanobodies) and gene silencing. Nanobodies are format-
ted anti-TNFα single-domain antibody fragments derived
from heavy-chain camelid antibodies. These molecules can
be cloned and produced easily as recombinant proteins in
bacteria and yeast, and are more stable than classical
antibodies. Lactococcus lactis was engineered to secrete
monovalent and bivalent murine (m)TNFα-neutralizing
nanobodies as therapeutic proteins. Nanobody-secreting
L. lactis was orally administered to mice and this resulted
in local and active delivery of anti-mTNFα nanobodies at
the mucosa of the colon, without measurable levels in
systemic circulation. Noteworthy, nanobodies did not
interfere even with systemic Salmonella infection
experimentally induced in colitic IL10−/− mice. The
L. lactis-secreted nanobodies seem to share the efficacy
of traditional anti-TNFα therapeutics, while lacking the
systemic adverse events.60
Gene silencing via RNA interference (RNAi) represents
another promising treatment strategy for intestinal inflam-
mation. RNAi obtained by means of orally delivered small (or
short) interfering RNA (siRNA), usually composed of
double-stranded 20–25 nucleotides, is a powerful tool for
post-transcriptionally silencing gene expression, interfering
with the expression of a specific gene, e.g., one that is
overexpressed in a certain diseases. One of the major
obstacles in siRNA therapy is low penetration of siRNA across
cell membranes.61 To overcome this problem, many delivery
systems engineered using nanotechnologies have been
investigated with promising results. The first study tried to
drive TNFα gene silencing directly onto inflammatory lesions
of experimental models of colitis, using as vector thioketal
NP that selectively degrades in response to reactive oxygen
species (ROS). Thioketal NPs are formulated from a new
polymer composed of ROS-sensitive thioketal linkages that
are stable to acid-, base-, and protease-catalyzed degrada-
tions. However, at sites of intestinal inflammation, the
elevated ROS levels produced by infiltrating phagocytes
trigger the degradation of the TNFα-thioketal NPs, thus
localizing the release of siRNA at the site of inflammation
with consequent inhibition of gene expression only in the
inflamed tissue.62 In a second study TNFα-siRNA was firstly
loaded into polylactide (PLA) (NP matrix) and then covered
with polyvinyl alcohol (PVA) (NP shell). The resulting NPs
were efficiently taken up by inflamed macrophages and,
interestingly, gene silencing was not found in the liver
confirming the low systemic bio-availability.63 Another
investigation used a new delivery system called
nanoparticles-in-microsphere oral system (NiMOS). siRNA
was encapsulated in gelatin NPs and further entrapped in
poly-caprolactone (PCL) microspheres. In this multi-
compartmental system, microspheres with sizes smaller
than 5 μm permit localization in the colon by a controlled
degradation of the outer layer and release of the gelatine
NPs to the site of inflammation once the PCL matrix is
degraded.64 Recently, NP containing TNFα-siRNA has been
Table 4 Systemic steroids.
Drug Vector Size
(z)
Model Results Ref.
Prednisolone Eudragit 568 nm Rat – In vitro and in vivo: release in colon.
– No evaluation of efficacy.
78
Dexamethasone PLA b4 μm DSS colitis – Amelioration of inflammation (histological score,
MPO activity, NO production, gene expression of
TNF-α, IL-1β, IFN-γ).
– Microspheres predominantly taken up into colon-
ic lymphoid tissue.
– Serum drug levels not increased.
79
PLA b4 μm TNBS colitis – Amelioration of inflammation (macroscopic and
histological score, MPO activity, NO production,
gene expression of TNF-α, IL-1β, IFN-γ,
COX-2, NF-KB).
80
Rheum
tanguticum
polysaccharide
Microspheres TNBS colitis – Amelioration of inflammation (macroscopic and
histological score, MPO and NF-κB activity),
reduces inflammatory Th1 cytokines
(TNF-α, IFN-γ).
81
Dexamethasone +
butyrate
Solid lipid
matrix (stearic
acid–butyrate)
80–60 nm
(−30 mV)
In vitro
peripheral blood
mononuclear
cells
– Reduces pro-inflammatory cytokines
(IL-1β and TNF-1α).
82
Dexamethasone Liposomes 100 nm DSS colitis – Aggravates inflammation. 83
PLA: poly-lactic acid; z: surface charge; DSS: dextran sodium sulfate; TNBS: trinitrobenzene sulfonic acid; MPO: myeloperoxidase; NO: nitric
oxide; TNFα: tumor necrosis factor α; IL: interleukin; IFN: interferon; COX: cyclooxygenase; NF-κB: nuclear factor-κB.
911Nanotechnology in IBDengineered also using the novel mannosylated polymer that,
as stated above, has a specific affinity to the mannose
receptors exclusively expressed on the surface of the
macrophages. This strategy, also called active targeting, is
able to increase the efficiency of delivery by selectivelyTable 5 Budesonide.
Vector Size
(z)
Model Res
PLGA vs liposomes 220 vs 190 nm In vitro model – P
– L
+/− Eudragit ~200 μm TNBS colitis – B
(
a
– M
PLGA-Eudragit
NPs vs
microparticles
290 nm vs
1.9 μm
TNBS colitis – I
(
– N
h
– N
– L
Solid lipid 200 nm
(z: −40 mV)
DSS colitis – I
– I
h
r
c
– S
Nano-fibers (Eudragit) 190 nm – S
– N
PLGA: poly(lactic-co-glycolic acid); NPs: nanoparticles; z: surface charge;
interleukin; MPO: myeloperoxidase; TNFα: tumor necrosis factor α.targeting the phagocytic cells of the inflammatory
infiltrate.65
Neutralization of other pro-inflammatory molecules, not
yet used in clinical practice, has been considered as target for
gene silencing via RNAi. One study concerned cyclin D1, a keyults Ref.
LGA reduces IL-8 to normal values for over 4 days.
iposomes worsen inflammation.
84
oth formulations ameliorate inflammation
macroscopic and histological score, MPO activity)
nd body weight.
PO activity better with Eudragit.
55
n vivo: amelioration of inflammation
macroscopic score, MPO activity) and body weight.
P penetration into inflamed colon 5 folds higher than
ealthy tissue.
Ps vs Microparticles: higher colon levels (15 folds).
ower systemic availability.
85
n vitro: 100% reduction of TNFα secretion.
n vivo: ameliorates inflammation (clinical and
istologic score, MPO activity),
educes pro-inflammatory
ytokines (IL-1β and TNF-α).
ustained presence over 12 h.
86
ustained and complete drug release in the colon.
ot evaluated the efficacy.
87
TNBS: trinitrobenzene sulfonic acid; DSS: dextran sodium sulfate; IL:
912 A. Viscido et al.cell cycle-regulating molecule, upregulated in both epithelial
and immune cells of IBD patients that has been implicated in
promoting inflammation and epithelial colorectal dysplasia.
The liposome-based NPs used to target cyclin D1-siRNA were
covered by antibodies toward β7 integrin, a receptor
specifically present on a leukocyte subset involved in gut
inflammation.66 A NiMOS using gelatin NPs was employed to
encapsulate contemporaneously the siRNA of both TNFα and
cyclin D1. The effect of cyclin D1 silencing was more potent
than that of TNFα indicating the important role of the
molecule in inflammation and the potential role for further
exploration as a target for future therapy strategies.67
Another effective gene target for NPs was the
mitogen-activated protein kinase kinase kinase kinase 4
(Map4k4), a mediator of cytokine expression. siRNA was
incorporated into the interior of porous, hollow glucan shells
purified from baker's yeast. Glucan has specific affinity to
receptors present on gut associated lymphoid tissue (GALT)
macrophages and dendritic cells, the so-called glucan-
receptors, involved in phagocytosis. Thus the introduction of
glucan to the surface of NPs provided selectivity for macro-
phages targeting.68
An alternative way to obtain gene silencing is that of
synthetic double-stranded antisense oligonucleotide using
plasmid DNA. Oligonucleotide directed toward nuclear
factor-κB (NF-κB) gene was encapsulated into NPs consisting
in chitosan-modified PLGA nanospheres. NPs resulted spe-
cifically deposited and adsorbed on the inflamed mucosal
tissue of the UC model rat.69
Administration of anti-inflammatory mediators repre-
sents another biologic strategy (Table 3). Interleukin
(IL)-10 is a cytokine that exerts potent anti-inflammatory
activity but its clinical use has been abandoned due to
important cytokine-related side-effects.70 Nanotechnology
could improve safety localizing the cytokine effect at the
site of inflammation avoiding systemic action. The intestinal
delivery of IL-10 by means of L. lactis genetically engineered
to secrete the cytokine, resulted effective in reducing the
therapeutic dose of IL-10, in ameliorating dextran sodium
sulfate (DSS) colitis, and in preventing the onset of colitis in
IL10−/− mice.71 Subsequently, IL-10 was delivered into
inflamed intestine using two strategies: the administration
of the cytokine itself or the administration of its coding
gene. Microspheres containing the protein IL-10 were able to
prevent colitis in IL-10 deficient mice after rectal adminis-
tration.72 IL-10-expressing plasmid DNA, encapsulated in
gelatin NPs and further entrapped in PCL microspheres
(NiMOS), was able to cure experimental colitis.73 More
recently IL-10 was encapsulated in a micro-particulate drug
delivery system using a novel Eudragit-coated gelatin
microparticle with the advantage of being inexpensive and
non-toxic. However, data on animal models are laking.74
Other interesting developments in this area may be
represented by new therapeutics pathways. One is the
induction of prohibitin production, a protein observed at
decreased levels in mucosal biopsies from IBD patients.
Prohibitin full length cDNA was cloned and encapsulated in
hydrogel PLA NPs. The NP preparation resulted similar to
that obtained by an adenoviral vector.75
Another good candidate therapeutics for acute colitis is
trefoil factor, a cytoprotective molecule that promotes
epithelial wound healing. The in situ secretion of trefoilfactor by intragastric administered L. lactis strains was
effective in a study on IBD animal models.76
Finally, Lys-Pro-Val (KPV) a C-terminal sequence of
α-melanocyte stimulating hormone able to inhibit NFκB
activation, bound to PLA-NPs and encapsulated into a
polysaccharide hydrogel vector containing alginate and
chitosan, resulted much more effective than free KPV in
reducing inflammatory responses induced by lipopolysac-
charide (LPS) in mice intestinal epithelia. The effective dose
of KPV-loaded NPs resulted 12,000 times lower than that of
KPV in free solution.77
Summarizing, although all these nanotechnology applica-
tion to biologic therapy are highly promising, many chal-
lenges still need to be addressed when using RNAi or plasmid
DNA to manipulate inflammation in vivo. Among these
challenges are immune toxicity and deposition of the
oligonucleotides and the NPs at the cellular level, which
needs to be carefully evaluated.612.3.2. Steroids
Tables 4 and 5 summarize studies on steroids. The
therapeutic strength of steroids in IBD is extensively
recognized, but its use is limited by serious side effects,
invariably arising after few weeks of treatment. To limit
these effects, nano- and microparticles were prepared with
systemic and topical corticosteroids and tried in experimen-
tal colitis.2.3.2.1. Systemic steroids. Prednisolone was prepared as
NP formulation by coating with pH responsive polymer
Eudragit S100. Mean size was of 568 nm. This formulation
of prednisolone effectively targeted drug to the colon and
provided effective way of treatment of experimental rat
colitis.78 Another experimental evaluation of target-specific
drug delivery to inflamed intestine was conducted using
dexamethasone encapsulated in PLA microspheres, and
administrated to mice with DSS or TNBS induced colitis.
The size of the microspheres was adjusted within 4 μm,
thereby permitting phagocytosis by macrophages. The
microsized delivery systems showed specificity for intestinal
inflammation with a tissue distribution of microspheres in
inflamed colon significantly higher than that in other organs.
The histological score, myeloperoxidase (MPO) activity,
expression of pro-inflammatory cytokines and nitric oxide
production were significantly lower in mice treated with
dexamethasone microspheres than in those treated with
dexamethasone alone.79,80 Dexamethasone was furthermore
encapsulated in microparticles prepared using Rheum
tanguticum polysaccharide, a traditional Chinese medicine
herb with colon delivery ability and immune-modulatory
effects. The polysaccharide microsphere delivered dexa-
methasone directly to the colon of TNBS experimental colitis
avoiding upper absorption and showing synergistic effects on
colitis.81 Dexamethasone, studied also in solid lipid NPs with
butyrate, resulted effective in counteract inflammatory
activity in a human IBD whole-blood model.82 However,
dexamethasone entrapped into liposomes, surprisingly wors-
ened a DSS-induced IBD model, likely for a preferential
uptake into a specific subset of macrophages, as hypothe-
sized by the authors.83
913Nanotechnology in IBD2.3.2.2. Topical steroids. Studies on budesonide were
addressed to demonstrate the ability of nano–microparticles
to take the drug distally in the gastroenteric tract, concen-
trate in inflamed tissues and treat colitis. Budesonide efficacy
was tested in in vitromodel for the inflamed intestinal mucosa
using three different pharmaceutical formulations: (a) free
drug solution, (b) encapsulated into PLGA NPs, and (c)
encapsulated into liposomes. The (c) PLGA-budesonide for-
mulation was found to be superior to both free budesonide
solution and liposome formulation with good efficacy for
recovery from inflammation and evidence of a depot effect for
drug release. The PLGA particles did not adhere to the healthy
model, but they specifically adhere to the inflamed model
tissue. It is noteworthy that liposomes-budesonide worsened
inflammation.84 This finding was likely due to liposome
toxicity, in line with the previously reported study in a DSS
mouse model of colitis.83 In animal models efficacy of
budesonide resulted inversely related to the size of the
carrier: NP-preparations resulted superior to microparticles
and these, in turn, superior respect to free budesonide.
Microsized budesonide, with or without encapsulation within
an enteric pH-sensitive polymer (Eudragit S100), determined a
significant improvement of inflammation in TNBS colitis
respect to the simple drug suspension. The most effective
formulation in reducing the MPO activity was budesonide
encapsulated within Eudragit.55 Nanosized budesonide,
engineered as pH-sensitive and time-dependent oral release,
was superior to microspheres preparation in alleviating TNBS
induced colitis. The higher anti-inflammatory effect was likely
due to a strong and specific adhesion of the nanospheres to the
ulcerated and inflamed mucosal tissue, leading also to lower
systemic availability of NPs respect to microspheres.85
Recently budesonide was loaded on NP solid lipid carriers, a
second generation of carriers with a higher stability and drug
loading. NPs had a size of 200 nm. In vitro, this formulation
reduced TNFα secretion by activated macrophages by aboutTable 6 Tacrolimus.
Vector Size
(z)
Model
Eudragit 150 μm TNBS colitis
PLGA ~107 nm TNBS and
oxazolone co
PLGA NPs encapsulated into
microparticles (Eudragit)
Cores: 250 nm
Capsule:
30–60 μm
TNBS colitis
PLGA NPs versus Eudragit NP ~450 nm
(z: close to
neutrality)
DSS colitis
PLGA: poly(lactic-co-glycolic acid); TNBS: trinitrobenzene sulfonic acid100%. In vivo, the NP solid lipid carrier was retained in
inflamed colon over 12 h and it was effective in reducing
inflammation in DSS-induced colitis.86 Finally, budesonide has
been loaded at a new system consisting of nano-fibers that, as
reported by authors, could be an oral colon-specific delivery
system superior to the current NP oral carriers.872.3.3. Immunosuppressant
2.3.3.1. Tacrolimus (Table 6). Microparticles were used to
deliver tacrolimus with the rationale that a more selective
delivery to the site of inflammation could improve efficiency
and tolerability reducing adverse events. Tacrolimus
entrapped into microspheres prepared with the pH-sensitive
polymer Eudragit P-4135F was compared to control rats
receiving the drug as a solution either by oral or by
subcutaneous route. The microsized formulations proved to
be as efficient in mitigating the experimental TNBS colitis as
the subcutaneous drug solution, and to be superior to drug
solution given by oral route. The tacrolimus-microsphere
group proved its potential to retain the drug from systemic
absorption as evidenced by reduced nephrotoxicity.88 Good
results were obtained also when tacrolimus was associated to
PLGA to deliver NPs into intestinal inflammation. Tacrolimus-
containing polymeric NPs were designed and tested for their
therapeutic efficiency in two different rat colitis models
(TNBS and oxazolone colitis) after oral or rectal administra-
tion. The therapeutic effect on both models was higher after
rectal administration respect to the oral route. However, NPs
allowed an enhanced and selective drug penetration into the
inflammation site as the drug had a 3-fold higher concentra-
tion respect to surrounding healthy tissue.89
An early study focused on a double-technique delivery
system by encapsulating tacrolimus first into PLGA NPs and
therefore entrapped into pH-sensitive microspheresResults Ref.
– Amelioration of inflammation (clinical activity
score, MPO).
– Reduced systemic absorption and adverse
events.
88
litis
– Amelioration of inflammation (clinical activity,
MPO, body weight).
– Rectal route better than oral.
– Drug concentration in inflamed site 3 fold
higher respect healthy tissue.
89
– Amelioration of inflammation (clinical activity,
MPO, body weight).
– High concentration of drug in inflamed site;
– Minimization of systemic adverse effects.
90
– PLGA sustained release over 24 h. Eudragit
release over 30 min.
– Both formulations ameliorate inflammation
(MPO, colon length).
– Eudragit showed lower adverse events.
91
; DSS: dextran sodium sulfate; MPO: myeloperoxidase.
914 A. Viscido et al.(Eudragit P-4135F). The size of the NPs resulted of about
250 nm and the microencapsulation of PLGA NPs resulted in
spherical particles. The microparticle containing NPs, with a
diameter varying between 30 and 60 μm, significantly
mitigated experimental colitis and allowed an efficient and
site specific release at the inflamed tissue area reducing the
systemic absorption of the drug.90 A subsequent experiment
compared tacrolimus containing PLGA NPs to Eudragit NPs in
DSS model colitis in mice. NP formulations were adminis-
tered orally, while control mice received the drug as a
solution either by oral or by subcutaneous route. Experi-
mental colitis improved after administration of all tacroli-
mus containing formulations. However, oral NP formulations
were less efficient in mitigating the experimental colitis
compared to subcutaneous drug solution but superior to drug
solution given by oral route. Tacrolimus solution groups
(oral/subcutaneous) exhibited increased levels of adverse
effects, whereas both NP groups demonstrated their poten-
tial to reduce nephrotoxicity, especially those with
pH-sensitive NPs.91
2.3.3.2. Cyclosporine. A NP composed of chitosan amphi-
phile has been developed to improve the oral absorption of
hydrophobic drugs like cyclosporine-A. This nanosized
formulation of cyclosporine was able to ameliorate the
dissolution rate, the adherence to the mucus layer, the
contact between the drug and the gastrointestinalTable 7 5-ASA.
Vector Size
(z)
Experimental model
Chitosan 200 μm Not used in animals
Chitosan b9 μm
(z: −30 mV)
TNBS colitis
Chitosan ~5 μm
(z: −21 mV)
TNBS colitis
Chitosan (core)
Eudragit (coating)
600 μm TNBS colitis
PCL 200–350 nm
(z: neutral)
TNBS colitis
Silica 140 nm TNBS colitis
Eudragit 100 and 400 nm Not used in animals
Diatom silica 10 μm
(z: −37 mV)
Not used in animals
5-ASA: 5-aminosalicylic acid; PCL: poly-caprolactone; z: surface chargepithelium absorptive cells, and the penetration into
mucosa.92 NPs were able to enhance the effect of
cyclosporine-A on alleviating the intestinal damage in
murine models of intestinal graft-versus-host disease.93
However, data on effect of cyclosporine on models of
intestinal inflammation are lacking.
2.3.4. Mesalazine
Table 7 summarizes studies on mesalazine. Studies on
mesalazine focused to further ameliorate the contact
between drug and inflamed tissues by increasing adhesion,
ameliorate delivery system and increase retention time. In
the first experiments 5-ASA was loaded to chitosan,
obtaining a marked improvement of drug efficacy in animal
models of colitis.94–96 5-ASA pellets containing chitosan
were also protected with pH-sensitive coating polymer
Eudragit FS to deliver 5-ASA into the colon. The mean
diameter of the pellets was about 600 μm. The chitosan–
core drug loaded pellets exhibited a 3.5-fold higher adhesion
to colonic inflamed tissue and a reduced systemic drug
exposure than chitosan free pellets. The pellets were also
able to ameliorate inflammation on TNBS rats colitis
model.97
Many subsequent studies confirmed an efficient colonic
targeting of NP formulation. In one of the first experimental
studies involving colitis in mice, 5-ASA at a dose of 0.5 mg/kg
bonded to PCL matrix polymer NPs (200–350 nm in size),Results Ref.
– In vitro: 80% release of the drug in the
presence of cecal secretions.
94
– Amelioration of inflammation (macroscopic,
histological and clinical scores, MPO activity);
– Dominant localization of 5-ASA in the
colon with low systemic bioavailability.
95
– Amelioration of inflammation (macroscopic,
histological and clinical scores, MPO activity);
– Excellent mucoadhesive properties to
inflamed intestine.
96
– Amelioration of inflammation (clinical score,
MPO activity);
– 3.5 fold higher adhesion to inflamed tissue
than chitosan free pellets.
97
– Amelioration of inflammation (histological
and clinical scores, MPO activity);
– NP-5-ASA 60 times more effective
than 5-ASA solution.
98
– Amelioration of inflammation (histological and
clinical scores, MPO activity);
– 6 fold higher adhesion to inflamed tissue;
– Higher efficacy (25 mg/kg NP-5-ASA better
than 100 mg/kg 5-ASA solution);
– Prolonged efficacy (retention in inflamed
tissue for more than 1 week).
99
– Obtained by a new and simple technique. 100
– In vitro: prolonged release of the drug. 101
e; TNBS: trinitrobenzene sulfonic acid; MPO: myeloperoxidase.
915Nanotechnology in IBDinduced a decrease of MPO activity similar to that obtained
with 5-ASA administered as a solution at a dose of 30 mg/kg,
thus resulting up to 60 times more effective.98 In a subsequent
investigation, the same research group tested the selective
delivery of 5-ASA bound by means of a biodegradable covalent
linkage to the modified surfaces of spherical 140 nm silica
NPs. When administered in vivo, histological analysis showed
the complex 5-ASA-silica-NPs to result in a six-fold higher
adhesion to inflamed tissue than in healthy control groups.
Moreover, such particles were found to remain within the
inflamed tissue for a week or more. These properties have the
effect of significantly lowering the therapeutically necessary
drug dose: complex 5-ASA-silica-NPs at drug doses of 25 or
50 mg/kg revealing better and more prolonged therapeutic
effects than 5-ASA administered in solution at a dose of
100 mg/kg.99 The pH sensitive polymer Eudragit S100, the
same adopted for conventional 5-ASA preparations, has been
also used to obtain a nanosized delivery system. Particles so
produced have yet to be tested for efficacy, but has recently
received increasing attention as an alternative to convention-
al processes.100 More recently, microparticles consisting in the
aquatic organism algae, the so called diatom silica micropar-
ticles, have been used to deliver 5-ASA and steroids. In vitro
studies suggest that, due to their porous surface, they could
be able to realize a sustained and controlled release
formulation.101
2.3.5. Unconventional Strategies
A clodronate loaded NP based on a cationic
polymethacrylate (Eudragit RL) with particle diameter
around 120 nm, was studied in murine experimental colitis
in vivo. This formulation was able to decrease inflammatory
activity in TNBS-colitis and oxazolone-colitis models while
free clodronate did not show a mitigating effect. Cell
culture experiments indicated that intracellular delivery of
clodronate was necessary to obtain an anti-inflammatory
effect.102
A microsized drug delivery system composed of
pH-sensitive material was used to incorporate low molecular
weight heparin in the attempt to reduce the risk of severe
hemorrhagic adverse effects. To this purpose, enoxaparin
was entrapped into pH-sensitive microspheres (100 to
400 μm) using Eudragit P4135F. This NP-drug complex
showed a selective oral delivery of heparin into the colon,
proving its efficacy as a new therapeutic strategy in IBD.103
2.4. First Experiences in Humans
The distribution of particles in humans (patients with active
UC, CD and healthy controls) not bound to an active drug has
been studied following rectal administration. The particles,
NPs and microparticles, were of spherical shape, composed
of PLGA, with average sizes of 250 nm and 3000 nm
(3.0 μm), respectively. Microscopy revealed no mucosal
binding of either NPs or microparticles in the healthy
controls, whereas bindings of both were found in areas of
epithelial lesions, suggesting persorption through cellular
voids of the inflamed mucosa. Interestingly, a clear
size-dependent difference regarding the accumulation of
particles within inflamed mucosa was observed, NPs pre-
vailing in the deeper regions with the larger microparticlesconfined to the more superficial areas. This phenomenon
probably reflects a size-dependent limitation of the
persorptive capacity of particles in general. Another
interesting observation was that accumulation of particles
turned out to be strictly related to the severity of the
lesions, with no particles found in normal IBD mucosa, minor
amounts in cases of mild-to-moderate disease, and marked
accumulation in cases of severe disease.
Overall, microparticles exhibit accumulation and
bioadhesion to the inflamed mucosal wall with no absorption
of these particles across the normal epithelial barrier,
whereas NPs are able to translocate to the serosal
compartment suggesting that the choice of size can
determine the extent of penetration in the intestinal wall.34
The same group of investigators studied the impact of the
modification of the surface chemical composition of the
particles on their uptake into the mucosa of IBD patients.
NPs sized 300 nm and microparticles sized 3.0 μm were
used. Three different types of surfaces were used for both
NPs and microparticles. The first type was the
non-functionalized PLGA surface, the same used in the
previous study. Chitosan- and PEG-functionalized surfaces
were the other two types. Chitosan surface confers a
positive charge to the particles with a consequent electro-
static affinity to negatively charged surfaces. PEG confers a
hydrophilic surface to the particles with an increased
transport through the mucus. The study demonstrated the
superiority of PEG-functionalized drug carriers in particle
translocation and deposition in inflamed mucosal tissues
compared to chitosan- and non-functionalized particles.
PEG-functionalized microparticles demonstrated a low
translocation into healthy tissues but a significantly in-
creased translocation into inflamed mucosal tissues. The
hydrophilic surface provides an accelerated translocation
into the leaky epithelium, and then into the core of the
intestinal inflammation.104
It can therefore be hypothesized that microparticles
could be useful in the cure of active disease where the
mechanism of persorption permits the passage of the larger
particles, whereas NPs could be more effective under
conditions of remission or minor inflammation where the
mucosal barrier is less permeable and absorption through
epithelial cells prevails with respect to persorption. Finally,
functionalization of the particles' surface using PEG, could
ameliorate the affinity to intestinal inflammation.
It is still to elucidate how geometry of the particles, the
third feature affecting NP kinetics and dynamics together
with size and composition, could influence and further
ameliorate their uptake in inflammatory tissue.1053. Conclusions
Clinical applications of nanotechnology are now on the verge
of becoming a reality, the promising data of experimental
findings awaiting confirmation in clinical trials. In the not
too distant future patients with IBD could be treated with
drugs targeted to only where they are needed, with the size
and structure of the delivery system modified according to
the severity of the disease, and with the opportunity for
increasing the therapeutic index of existing drugs so as to
obtain the desired pharmacologic effects with smaller doses
916 A. Viscido et al.and consequentially reduced side effects and risk/effect
ratios. The longer lasting permanence of the drug within the
mucosa could have the additional effect of reducing both the
number of pills to be taken and their frequency of
administration, thereby improving adherence to treatment.
Furthermore, an oral administration could be available also
for biologics that, together with a specific target for
inflamed tissues could improve both safety and efficacy.
Taken together, these findings represent a potentially
significant advance in the treatment of IBD, offering the
prospect to patients of stable and prolonged remissions with
a reduced drug load.
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